CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
Go back to CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study| Eaton Vance Dividend Builder Fd Cl C (NASDAQ: CTMX) | Delayed: 3.57 +0.18 (5.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.39 | 52 Week High | $24.68 | |||
| Open | $3.48 | 52 Week Low | $9.10 | |||
| Day High | $3.60 | P/E | N/A | |||
| Day Low | $3.46 | EPS | $0.00 | |||
| Volume | 4,579,146 | |||||
